Take Part in this Workplace Survey from One Nucleus Member, Singular Talent
There’s change in the air. We’re predicting that your work and workplace will see momentous changes to meet what people expect from their employer.
Why?
Employees are looking for not only flexibility at work but a need for more autonomy. How this will affect leadership and longstanding working practices in management raises some interesting questions … it’s poised to change daily life at work for you, your team, and your manager…
And there’s yet more signs of evolution in the…
Blog by Alicia Gailliez, Business Development Manager, One Nucleus
You probably will not have read many blogs recently that start with a forest fire analogy, especially one targeted towards a Life Science audience, but here goes! On my recent trip to Yellowstone National Park, we learnt about the fires of 1988. Although devastating, the fires were an unprecedented chance to study the ecological impacts in an ecosystem and it was found that the environment would regenerate in a different way and one that could sustain a greater diversity of vegetation. This re-orientation can be…
Blog by Tony Jones, CEO, One Nucleus
January 2021 saw the launch of the One Nucleus Virtual Innovation Centre (VIC) created to provide a means for growing life science R&D companies to connect with and leverage the breadth of the One Nucleus ecosystem. A complementary offering to the variety of Innovation Centre, Accelerator and Incubator-style initiatives that are established and collated at a national level in the BIA Innovation Map, recognising that the need for support isn’t essentially time or set programme limited and requires those businesses to integrate into a coordinated…
Guest blog post by Chris Cooper, Scientific Specialist II, Immunotoxicology & Immunology, Labcorp Early Development Laboratories Ltd
In our previous post, we outlined the dangers of Cytokine Release Syndrome (CRS) and the importance of preclinical Cytokine Release Assays (CRAs) when developing monoclonal antibodies (mAbs) that interact with the patient’s immune system. In this second post, we describe the different kinds of assays in use and how these may fit into your drug development program. An alternative type of CRA, peripheral blood mononuclear cell (PBMC) blood…